AF 疗效试验的手术消融 (SAFE)
SAFE is an international multicentre RCT of concomitant surgical atrial fibrillation (AF) ablation in patients with paroxysmal or persistent AF undergoing cardiac surgery.
研究概览
详细说明
Atrial fibrillation (AF) affects more than 1% of the general population and is an important risk factor for stroke. AF prevalence increases with age, occurring in 10 to 15% of patients older than 80 years of age, which is important with the aging population. Of patients undergoing cardiac surgery, 10.8% have a history of AF. AF is believed to cause the left atrium to dilate and lose its transport function. AF significantly increases the risk of ischemic stroke of cardioembolic origin, but is also associated with heart failure and impairs quality of life. Although the causal relationship between the 2 clinical entities has not been fully elucidated, AF is believed to cause heart failure via several mechanisms.
Ablation of AF is the application of scars to the atrial tissue to disrupt faulty electrical signals that cause the arrhythmia. If surgical ablation of AF yields a benefit similar to catheter-based AF ablation, thousands of people undergoing cardiac surgery could benefit from this procedure each year. SAFE will be a landmark trial in cardiac surgery, definitely establishing surgical AF ablation's impact on cardiovascular outcomes. Cardiac surgery is the optimal setting to establish whether maintenance of sinus rhythm through AF ablation yields clinical benefit, and is a setting where sham-control is possible. This will not only provide evidence for the cardiac surgical patients but will bolster the evidence for ablation (catheter or stand-alone surgical) in other AF patients.
The intervention under investigation is concomitant surgical AF ablation which is compared to no surgical AF ablation. The primary outcome is hospital readmissions with heart failure during 4 years of follow-up. This study will enroll 2000 patients from 50 centres, globally. Patients will be followed at hospital discharge, 4 to 6 weeks after surgery, 6 months after surgery, and then at 6-month intervals until the final follow-up visit, for a median follow-up for 4 years.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Richard Whitlock
- 电话号码:905-521-2100
- 邮箱:Richard.Whitlock@phri.ca
研究联系人备份
- 姓名:SAFE Coordinators
- 邮箱:SAFE@phri.ca
学习地点
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8L 2X2
- 招聘中
- Hamilton General Hospital
-
接触:
- Richard Whitlock, MD PhD FRCSC
- 电话号码:40306 905-527-4322
- 邮箱:richard.whitlock@phri.ca
-
首席研究员:
- Richard Whitlock, MD MSc FRCSC
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 18 years;
- Undergoing a clinically indicated cardiac surgical procedure: CABG, AVR, ascending aorta replacement, or combinations thereof;
- Documented history of paroxysmal or persistent AF
- Provide informed consent
Exclusion Criteria:
-
Dominant atrial arrhythmia is atrial flutter;
-
Documented left atrial diameter ≥ 6 cm;
-
Previous cardiac surgery requiring opening of the pericardium;
-
Patients undergoing any of the following procedures:
- Heart transplant
- Complex congenital heart surgery
- Sole indication for surgery is ventricular assist device insertion
- Mitral valve repair or replacement
- Tricuspid valve repair or replacement
-
Patient resides in a long-term care facility
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Surgical Atrial Fibrillation Ablation Group
Surgeon will perform left atrial ablation during patient's cardiac surgery procedure. |
Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed. |
|
无干预:No Surgical Atrial Fibrillation Ablation Group
Surgeon will not perform left atrial ablation during the patient's cardiac surgery procedure. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of hospital readmissions for heart failure over duration of follow-up
大体时间:Common termination point for trial (median follow-up of 4 years)
|
Total number of hospital readmissions for heart failure. |
Common termination point for trial (median follow-up of 4 years)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Ischemic stroke or systemic arterial embolism events over duration of follow up
大体时间:Common termination point for trial (median follow-up of 4 years)
|
Number of Ischemic stroke or systemic arterial embolism events over duration of follow up |
Common termination point for trial (median follow-up of 4 years)
|
|
Length of ICU stay
大体时间:From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
Length of ICU stay, including readmissions, from study intervention surgery to hospital discharge, including readmissions |
From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
|
Length of hospital stay
大体时间:From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
Length of hospital stay |
From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
|
Freedom from recurrence of atrial tachyarrhythmia
大体时间:1 year post-operatively
|
Freedom from recurrence of atrial tachyarrhythmia |
1 year post-operatively
|
|
Number of days free from admission to healthcare facility or presentation to the emergency department for heart failure
大体时间:Common termination point for trial (median follow-up of 4 years)
|
Number of days free admission to healthcare facility or presentation to the emergency department for heart failure |
Common termination point for trial (median follow-up of 4 years)
|
|
All-cause mortality
大体时间:Common termination point for trial (median follow-up of 4 years)
|
All-cause mortality |
Common termination point for trial (median follow-up of 4 years)
|
|
Cardiovascular mortality
大体时间:Common termination point for trial (median follow-up of 4 years)
|
Cardiovascular mortality |
Common termination point for trial (median follow-up of 4 years)
|
|
Antiarrhythmic drug use
大体时间:Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)
|
Antiarrhythmic drug use |
Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)
|
|
Number of patients undergoing atrial fibrillation ablation
大体时间:90 days post- study surgery until common termination point for trial (median follow-up of 4 years)
|
Number of patients undergoing atrial fibrillation ablation |
90 days post- study surgery until common termination point for trial (median follow-up of 4 years)
|
|
Quality of Life - atrial fibrillation specific
大体时间:At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Atrial fibrillation specific quality of life as assessed by the Atrial Fibrillation Effect on QualiTy of Life questionnaire (AFEQT) which is 20 questions using a 7 point Likert scale where a higher score means a worse outcome. |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Quality of Life - heart failure specific
大体时间:At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Heart failure specific quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) which is a 12 questions using Likert scales where a higher score is a better outcome. |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Quality of Life - General
大体时间:At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Quality of life- general as assessed by the European quality of life index version 5D (EQ-5D-5L) which consists of a descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Ischemic stroke and systemic arterial embolism
大体时间:Up to 30 days post-operatively
|
Safety outcome |
Up to 30 days post-operatively
|
|
Number of patients requiring permanent pacemaker implantation
大体时间:Up to 1 year post-operatively
|
Safety outcome |
Up to 1 year post-operatively
|
|
Volume of chest tube output
大体时间:Up to 24 hours post-operatively
|
Safety outcome - chest tube output measured in mL. |
Up to 24 hours post-operatively
|
|
Re-operation for bleeding
大体时间:From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
Safety outcome |
From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
|
|
All-cause mortality
大体时间:Prior to discharge or within 30 days post-operatively (whichever occurs first)
|
Safety outcome |
Prior to discharge or within 30 days post-operatively (whichever occurs first)
|
|
Post-operative major bleeding
大体时间:<48 hours after surgery
|
Safety outcome |
<48 hours after surgery
|
|
Number of patients with pulmonary vein stenosis
大体时间:At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Safety outcome |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Number of patients with stiff left atrium syndrome
大体时间:At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Safety outcome |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Number of patients with esophageal to atrial fistula
大体时间:At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
Safety outcome |
At 1 year, and at common termination point for trial (median follow-up of 4 years)
|
|
Health economic analysis of surgical atrial fibrillation
大体时间:At 1 year, and at common termination point (median follow-up of 4 years)
|
Economic analysis will be assessed via health care utilization by patients |
At 1 year, and at common termination point (median follow-up of 4 years)
|
|
Health economic analysis of surgical atrial fibrillation
大体时间:At 1 year, and at common termination point (median follow-up of 4 years)
|
Economic analysis will be assessed via a questionnaire of health care visits and costs incurred by patients. |
At 1 year, and at common termination point (median follow-up of 4 years)
|
合作者和调查者
调查人员
- 首席研究员:Richard Whitlock、Population Health Research Institute
- 首席研究员:Emilie Belley-Côté、Population Health Research Institute
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.